Cargando…

Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice

A clinical challenge remains in the treatment of hypoxic–ischemic brain injury in newborns. Nicotinamide adenine dinucleotide (NAD(+)) has beneficial effects in animal models of adult stroke. Here, we aimed to understand the short- and long-term neuroprotective effects of NAD(+)-promoting substance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Takuya, Singh Mallah, Gagandeep, Ardalan, Maryam, Chumak, Tetyana, Svedin, Pernilla, Jonsson, Lina, Jabbari Shiadeh, Seyedeh Marziyeh, Goretta, Fanny, Ikeda, Tomoaki, Hagberg, Henrik, Sandberg, Mats, Mallard, Carina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548811/
https://www.ncbi.nlm.nih.gov/pubmed/37787108
http://dx.doi.org/10.1177/17590914231198983
_version_ 1785115354321649664
author Kawamura, Takuya
Singh Mallah, Gagandeep
Ardalan, Maryam
Chumak, Tetyana
Svedin, Pernilla
Jonsson, Lina
Jabbari Shiadeh, Seyedeh Marziyeh
Goretta, Fanny
Ikeda, Tomoaki
Hagberg, Henrik
Sandberg, Mats
Mallard, Carina
author_facet Kawamura, Takuya
Singh Mallah, Gagandeep
Ardalan, Maryam
Chumak, Tetyana
Svedin, Pernilla
Jonsson, Lina
Jabbari Shiadeh, Seyedeh Marziyeh
Goretta, Fanny
Ikeda, Tomoaki
Hagberg, Henrik
Sandberg, Mats
Mallard, Carina
author_sort Kawamura, Takuya
collection PubMed
description A clinical challenge remains in the treatment of hypoxic–ischemic brain injury in newborns. Nicotinamide adenine dinucleotide (NAD(+)) has beneficial effects in animal models of adult stroke. Here, we aimed to understand the short- and long-term neuroprotective effects of NAD(+)-promoting substance nicotinamide mononucleotide (NMN) in a well-established brain injury model in neonatal mice. Postnatal day (PND) 9 male and female mice were subjected to cerebral hypoxia–ischemia and treated with saline or NMN (50 mg/kg) immediately after hypoxia–ischemia. At different time points after hypoxia–ischemia, hippocampal NAD(+), caspase-3 activity, protein expression of SIRT1, SIRT6, release of high mobility group box-1 (HMGB1), long-term neuropathological outcome, short-term developmental behavior, and long-term motor and memory function were evaluated. Neonatal hypoxia–ischemia reduced NAD(+) and SIRT6 levels, but not SIRT1, in the injured hippocampus, while HMGB1 release was significantly increased. NMN treatment normalized hippocampal NAD(+) and SIRT6 levels, while caspase-3 activity and HMGB1 release were significantly reduced. NMN alleviated tissue loss in the long-term and improved early developmental behavior, as well as motor and memory function. This study shows that NMN treatment provides neuroprotection in a clinically relevant neonatal animal model of hypoxia–ischemia in mice suggesting as a possible novel treatment for neonatal brain injury. SUMMARY STATEMENT: Neonatal hypoxia–ischemia reduces nicotinamide adenine dinucleotide (NAD(+)) and SIRT6 levels in the injured hippocampus. Hippocampal high mobility group box-1 (HMGB1) release is significantly increased after neonatal hypoxia–ischemia. Nicotinamide mononucleotide (NMN) treatment normalizes hippocampal NAD(+) and SIRT6 levels, with significant decrease in caspase-3 activity and HMGB1 release. NMN improves early developmental behavior, as well as motor and memory function.
format Online
Article
Text
id pubmed-10548811
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-105488112023-10-05 Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice Kawamura, Takuya Singh Mallah, Gagandeep Ardalan, Maryam Chumak, Tetyana Svedin, Pernilla Jonsson, Lina Jabbari Shiadeh, Seyedeh Marziyeh Goretta, Fanny Ikeda, Tomoaki Hagberg, Henrik Sandberg, Mats Mallard, Carina ASN Neuro Original Papers A clinical challenge remains in the treatment of hypoxic–ischemic brain injury in newborns. Nicotinamide adenine dinucleotide (NAD(+)) has beneficial effects in animal models of adult stroke. Here, we aimed to understand the short- and long-term neuroprotective effects of NAD(+)-promoting substance nicotinamide mononucleotide (NMN) in a well-established brain injury model in neonatal mice. Postnatal day (PND) 9 male and female mice were subjected to cerebral hypoxia–ischemia and treated with saline or NMN (50 mg/kg) immediately after hypoxia–ischemia. At different time points after hypoxia–ischemia, hippocampal NAD(+), caspase-3 activity, protein expression of SIRT1, SIRT6, release of high mobility group box-1 (HMGB1), long-term neuropathological outcome, short-term developmental behavior, and long-term motor and memory function were evaluated. Neonatal hypoxia–ischemia reduced NAD(+) and SIRT6 levels, but not SIRT1, in the injured hippocampus, while HMGB1 release was significantly increased. NMN treatment normalized hippocampal NAD(+) and SIRT6 levels, while caspase-3 activity and HMGB1 release were significantly reduced. NMN alleviated tissue loss in the long-term and improved early developmental behavior, as well as motor and memory function. This study shows that NMN treatment provides neuroprotection in a clinically relevant neonatal animal model of hypoxia–ischemia in mice suggesting as a possible novel treatment for neonatal brain injury. SUMMARY STATEMENT: Neonatal hypoxia–ischemia reduces nicotinamide adenine dinucleotide (NAD(+)) and SIRT6 levels in the injured hippocampus. Hippocampal high mobility group box-1 (HMGB1) release is significantly increased after neonatal hypoxia–ischemia. Nicotinamide mononucleotide (NMN) treatment normalizes hippocampal NAD(+) and SIRT6 levels, with significant decrease in caspase-3 activity and HMGB1 release. NMN improves early developmental behavior, as well as motor and memory function. SAGE Publications 2023-10-03 /pmc/articles/PMC10548811/ /pubmed/37787108 http://dx.doi.org/10.1177/17590914231198983 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Kawamura, Takuya
Singh Mallah, Gagandeep
Ardalan, Maryam
Chumak, Tetyana
Svedin, Pernilla
Jonsson, Lina
Jabbari Shiadeh, Seyedeh Marziyeh
Goretta, Fanny
Ikeda, Tomoaki
Hagberg, Henrik
Sandberg, Mats
Mallard, Carina
Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title_full Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title_fullStr Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title_full_unstemmed Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title_short Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice
title_sort therapeutic effect of nicotinamide mononucleotide for hypoxic–ischemic brain injury in neonatal mice
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548811/
https://www.ncbi.nlm.nih.gov/pubmed/37787108
http://dx.doi.org/10.1177/17590914231198983
work_keys_str_mv AT kawamuratakuya therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT singhmallahgagandeep therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT ardalanmaryam therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT chumaktetyana therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT svedinpernilla therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT jonssonlina therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT jabbarishiadehseyedehmarziyeh therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT gorettafanny therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT ikedatomoaki therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT hagberghenrik therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT sandbergmats therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice
AT mallardcarina therapeuticeffectofnicotinamidemononucleotideforhypoxicischemicbraininjuryinneonatalmice